Heightened fire probability in Indonesia in non-drought conditions: the effect of increasing temperatures

In Indonesia, drought driven fires occur typically during the warm phase of the El Niño Southern Oscillation. This was the case of the events of 1997 and 2015 that resulted in months- long hazardous atmospheric pollution levels in Equatorial Asia and record greenhouse gas emissions. Nonetheless, anomalously active fire seasons have also been observed in non-drought years. In this work, we investigated the impact of temperature on fires and found that when the July–October (JASO) period is anomalously dry, the sensitivity of fires to temperature is modest. In contrast, under normal-to-wet conditions, fire probability increases sharply when JASO is anomalously warm. This describes a regime in which an active fire season is not limited to drought years. Greater susceptibility to fires in response to a warmer environment finds support in the high evapotranspiration rates observed in normal-to-wet and warm conditions in Indonesia. We also find that fire probability in wet JASOs would be considerably less sensitive to temperature were not for the added effect of recent positive trends. Near-term regional climate projections reveal that, despite negligible changes in precipitation, a continuing warming trend will heighten fire probability over the next few decades especially in non-drought years. Mild fire seasons currently observed in association with wet conditions and cool temperatures will become rare events in Indonesia

Decadal covariability of Atlantic SSTs and western Amazon dry-season hydroclimate in observations and CMIP5 simulations

The unusual severity and return time of the 2005 and 2010 dry-season droughts in western Amazon is attributed partly to decadal climate fluctuations and a modest drying trend. Decadal variability of western Amazon hydroclimate is highly correlated to the Atlantic sea surface temperature (SST) north-south gradient (NSG). Shifts of dry and wet events frequencies are also related to the NSG phase, with a 66% chance of 3+ years of dry events per decade when NSG > 0 and 19% when NSG < 0. The western Amazon and NSG decadal covariability is well reproduced in general circulation models (GCMs) historical (HIST) and preindustrial control (PIC) experiments of the Coupled Model Intercomparison Project Phase 5 (CMIP5). The HIST and PIC also reproduce the shifts in dry and wet events probabilities, indicating potential for decadal predictability based on GCMs. Persistence of the current NSG positive phase favors above normal frequency of western Amazon dry events in coming decades

Progressive Purkinje Cell Degeneration in tambaleante Mutant Mice Is a Consequence of a Missense Mutation in HERC1 E3 Ubiquitin Ligase

The HERC gene family encodes proteins with two characteristic domains: HECT and RCC1-like. Proteins with HECT domains have been described to function as ubiquitin ligases, and those that contain RCC1-like domains have been reported to function as GTPases regulators. These two activities are essential in a number of important cellular processes such as cell cycle, cell signaling, and membrane trafficking. Mutations affecting these domains have been found associated with retinitis pigmentosa, amyotrophic lateral sclerosis, and cancer. In humans, six HERC genes have been reported which encode two subgroups of HERC proteins: large (HERC1-2) and small (HERC3-6). The giant HERC1 protein was the first to be identified. It has been involved in membrane trafficking and cell proliferation/growth through its interactions with clathrin, M2-pyruvate kinase, and TSC2 proteins. Mutations affecting other members of the HERC family have been found to be associated with sterility and growth retardation. Here, we report the characterization of a recessive mutation named tambaleante, which causes progressive Purkinje cell degeneration leading to severe ataxia with reduced growth and lifespan in homozygous mice aged over two months. We mapped this mutation in mouse chromosome 9 and then performed positional cloning. We found a G⇔A transition at position 1448, causing a Gly to Glu substitution (Gly483Glu) in the highly conserved N-terminal RCC1-like domain of the HERC1 protein. Successful transgenic rescue, with either a mouse BAC containing the normal copy of Herc1 or with the human HERC1 cDNA, validated our findings. Histological and biochemical studies revealed extensive autophagy associated with an increase of the mutant protein level and a decrease of mTOR activity. Our observations concerning this first mutation in the Herc1 gene contribute to the functional annotation of the encoded E3 ubiquitin ligase and underline the crucial and unexpected role of this protein in Purkinje cell physiology

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Background: The impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on postoperative recovery needs to be understood to inform clinical decision making during and after the COVID-19 pandemic. This study reports 30-day mortality and pulmonary complication rates in patients with perioperative SARS-CoV-2 infection. Methods: This international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. The primary outcome measure was 30-day postoperative mortality and was assessed in all enrolled patients. The main secondary outcome measure was pulmonary complications, defined as pneumonia, acute respiratory distress syndrome, or unexpected postoperative ventilation. Findings: This analysis includes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8% (268 of 1128). Pulmonary complications occurred in 577 (51·2%) of 1128 patients; 30-day mortality in these patients was 38·0% (219 of 577), accounting for 81·7% (219 of 268) of all deaths. In adjusted analyses, 30-day mortality was associated with male sex (odds ratio 1·75 [95% CI 1·28–2·40], p\textless0·0001), age 70 years or older versus younger than 70 years (2·30 [1·65–3·22], p\textless0·0001), American Society of Anesthesiologists grades 3–5 versus grades 1–2 (2·35 [1·57–3·53], p\textless0·0001), malignant versus benign or obstetric diagnosis (1·55 [1·01–2·39], p=0·046), emergency versus elective surgery (1·67 [1·06–2·63], p=0·026), and major versus minor surgery (1·52 [1·01–2·31], p=0·047). Interpretation: Postoperative pulmonary complications occur in half of patients with perioperative SARS-CoV-2 infection and are associated with high mortality. Thresholds for surgery during the COVID-19 pandemic should be higher than during normal practice, particularly in men aged 70 years and older. Consideration should be given for postponing non-urgent procedures and promoting non-operative treatment to delay or avoid the need for surgery. Funding: National Institute for Health Research (NIHR), Association of Coloproctology of Great Britain and Ireland, Bowel and Cancer Research, Bowel Disease Research Foundation, Association of Upper Gastrointestinal Surgeons, British Association of Surgical Oncology, British Gynaecological Cancer Society, European Society of Coloproctology, NIHR Academy, Sarcoma UK, Vascular Society for Great Britain and Ireland, and Yorkshire Cancer Research

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Assemblage convectif de colloïdes par forces de capillarité en milieu confiné (applications en plasmonique)

Les nanomatériaux représentent un sujet de recherche en plein essor dans des domaines variés : D'une part, la miniaturisation augmente la vitesse de transmission et le stockage de l'information dans les technologies de la communication. D'autre part, la réduction en taille des matériaux révèle des propriétés physiques (optiques, électriques, etc.) nouvelles et étonnantes qui ouvrent la voie à de nombreuses applications (dispositifs nanoélectroniques, capteurs moléculaires etc.). Un grand défi consiste à fabriquer ou intégrer des nanostructures fonctionnelles afin d'exploiter leurs propriétés physiques intrinsèques. Dans ce contexte, nous avons développé une nouvelle approche de nanofabrication à partir de nanomatériaux colloïdaux basée sur l'assemblage par forces de capillarité. Cette technique consiste à contrôler l'évaporation en milieu confiné d'une suspension colloïdale sur un substrat lithographié grâce à un dispositif thermoélectrique associé à un système d'aspiration d'air. Les phénomènes physiques mis en jeu pendant l'assemblage ont été étudiés aussi bien à l'échelle macro- que nano-scopique. Ainsi, la température et le débit d'aspiration se sont révélés être des paramètres complémentaires pour le contrôle de l'évaporation, le déplacement de la ligne de contact, l'angle de contact et le mouvement colloïdal. De cette manière, des colloïdes de taille et nature (or et polystyrène allant de 50 nm à 1 m) variées ont été assemblés dans des structures complexes. En particulier, des objets métalliques déterministes ont été crées afin d'étudier leurs interactions plasmoniques. Des dimères d'or de distance inter-particule variable ont démontré un fort couplage plasmonique.Nanomaterials represent a thriving field of research in various areas: On the one hand, miniaturization increases transmission speed and information storage in the field of communication technologies. On the other hand, materials size reduction reveals new and remarkable physical properties (optical, electrical, etc.) that open the way for a variety of applications (nanoelectronic devices, molecular sensors, etc.). A major challenge is the fabrication or the integration of functional nanostructures in order to exploit their intrinsic properties. In line with this context, we developed a nanofabrication approach from colloidal suspensions that is based on the capillary force assembly technique. This new approach consists in controlling in confined medium the evaporation of a colloidal suspension onto a pre-patterned substrate via a thermoelectric device associated to an air-suction system. The physical phenomena that take place during the assembly were studied at the macro- as well as at the nano-scale. Thus, temperature and air-suction flow were acknowledged as complementary parameters for controlling the evaporation, contact-line displacement, contact-angle and colloidal motion. In this way, colloids of various materials and sizes (gold and polystyrene from 50 nm up to 1 m) were assembled into complex structures. In particular, deterministic metallic objects were created in order to study their plasmonic interactions. Gold dimers with variable inter-particle distances showed a strong plasmonic coupling.GRENOBLE1-BU Sciences (384212103) / SudocSudocFranceF